Permira funds to acquire European CNS specialty pharmaceutical company Neuraxpharm

This article was originally published here

Financial details of the transaction were not disclosed. With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer

The post Permira funds to acquire European CNS specialty pharmaceutical company Neuraxpharm appeared first on Pharmaceutical Business review.